Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNYSE:HSP
CUSIP44106010
Phone+1-847-9376472
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins12.15%
Return on Equity16.51%
Return on Assets8.65%
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Hospira (NYSE:HSP) Frequently Asked Questions
What is Hospira's stock symbol?
Hospira trades on the New York Stock Exchange (NYSE) under the ticker symbol "HSP."
How were Hospira's earnings last quarter?
Hospira, Inc. (NYSE:HSP) posted its earnings results on Wednesday, July, 29th. The healthcare company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.07. The healthcare company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Hospira had a net margin of 12.15% and a return on equity of 16.51%. Hospira's revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.72 EPS. View Hospira's Earnings History.
Has Hospira been receiving favorable news coverage?
Media headlines about HSP stock have trended positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hospira earned a news sentiment score of 0.35 on Accern's scale. They also gave news articles about the healthcare company an impact score of 48.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Hospira?
Shares of HSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hospira's stock price today?
One share of HSP stock can currently be purchased for approximately $89.96.
How big of a company is Hospira?
Hospira has a market capitalization of $15.56 billion.
How can I contact Hospira?
Hospira's mailing address is 275 N Field Dr, LAKE FOREST, IL 60045-2579, United States. The healthcare company can be reached via phone at +1-847-9376472.
MarketBeat Community Rating for Hospira (HSP)
MarketBeat's community ratings are surveys of what our community members think about Hospira and other stocks. Vote "Outperform" if you believe HSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hospira (NYSE:HSP) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/25/2016 forward)
Hospira (NYSE:HSP) Earnings History and Estimates Chart
Hospira (NYSE HSP) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/29/2015 | Q215 | $0.78 | $0.85 | $1.18 billion | $1.20 billion | View | N/A |  |
| 4/28/2015 | Q115 | $0.51 | $0.97 | $1.08 billion | $1.18 billion | View | N/A | |
| 2/12/2015 | Q414 | $0.41 | $0.53 | $1.12 billion | $1.13 billion | View | Listen | |
| 11/6/2014 | Q314 | $0.53 | $0.74 | $1.08 million | $1.15 billion | View | Listen | |
| 7/30/2014 | Q214 | $0.56 | $0.72 | $1.05 billion | $1.14 billion | View | Listen | |
| 4/30/2014 | Q114 | $0.49 | $0.60 | $1.02 billion | $1.10 billion | View | Listen | |
| 2/12/2014 | Q413 | $0.50 | $0.51 | $1.06 billion | $1.10 billion | View | Listen | |
| 11/6/2013 | Q3 2013 | $0.45 | $0.51 | $993.94 million | $1.0082 billion | View | N/A | |
| 7/31/2013 | Q2 2013 | $0.51 | $0.55 | $1.03 billion | $1.03 billion | View | Listen | |
| 5/1/2013 | Q1 2013 | $0.44 | $0.52 | $979.33 million | $884.00 million | View | Listen | |
| 2/13/2013 | Q4 2012 | $0.54 | $0.55 | $1.04 billion | $1.10 billion | View | Listen | |
| 11/7/2012 | Q312 | $0.45 | $0.47 | $987.67 million | $994.00 million | View | N/A | |
| 8/1/2012 | | $0.49 | $0.51 | | | View | N/A | |
| 5/1/2012 | | $0.46 | $0.47 | | | View | N/A | |
| 2/14/2012 | | $0.47 | $0.51 | | | View | N/A | |
| 10/26/2011 | | $0.95 | $0.66 | | | View | N/A | |
| 7/27/2011 | | $0.79 | $0.94 | | | View | N/A | |
| 4/26/2011 | | $0.78 | $0.93 | | | View | N/A | |
| 2/2/2011 | | $0.93 | $0.77 | | | View | N/A | |
| 10/26/2010 | Q3 2010 | $0.69 | $0.74 | | | View | N/A | |
| 7/28/2010 | Q2 2010 | $0.79 | $0.86 | | | View | N/A | |
| 4/27/2010 | Q1 2010 | $0.72 | $0.94 | | | View | N/A | |
| 2/4/2010 | Q4 2009 | $0.70 | $0.87 | | | View | N/A | |
| 10/27/2009 | Q3 2009 | $0.68 | $0.90 | | | View | N/A | |
| 7/29/2009 | Q2 2009 | $0.60 | $0.73 | | | View | N/A | |
| 4/28/2009 | Q1 2009 | $0.54 | $0.60 | | | View | N/A | |
| 2/17/2009 | Q4 2008 | $0.76 | $0.78 | | | View | N/A | |
| 11/5/2008 | Q3 2008 | $0.63 | $0.63 | | | View | N/A | |
| 8/6/2008 | Q2 2008 | $0.62 | $0.57 | | | View | N/A | |
| 5/7/2008 | Q1 2008 | $0.54 | $0.55 | | | View | N/A | |
| 2/28/2008 | Q4 2007 | $0.57 | $0.63 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Hospira (NYSE:HSP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Hospira (NYSE HSP) Insider Trading and Institutional Ownership History
Hospira (NYSE HSP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/2/2015 | Matthew R Stober | SVP | Sell | 21,833 | $87.49 | $1,910,169.17 | | |
| 2/27/2015 | Matthew R Stober | SVP | Sell | 25,338 | $87.47 | $2,216,314.86 | | |
| 2/17/2015 | Thomas E Werner | CFO | Sell | 1,566 | $87.35 | $136,790.10 | | |
| 1/15/2015 | Thomas E Werner | CFO | Sell | 10,000 | $61.56 | $615,600.00 | | |
| 1/12/2015 | Matthew R Stober | SVP | Sell | 2,000 | $61.80 | $123,600.00 | | |
| 12/15/2014 | Thomas E Werner | CFO | Sell | 10,000 | $60.86 | $608,600.00 | | |
| 12/2/2014 | Richard J Hoffman | CAO | Sell | 21,850 | $60.32 | $1,317,992.00 | | |
| 11/25/2014 | Marc J Yoskowitz | SVP | Sell | 11,523 | $59.93 | $690,573.39 | | |
| 11/24/2014 | Kenneth F Meyers | SVP | Sell | 46,250 | $59.66 | $2,759,275.00 | | |
| 11/17/2014 | Thomas E Werner | CFO | Sell | 10,000 | $57.73 | $577,300.00 | | |
| 9/15/2014 | Thomas E Werner | CFO | Sell | 10,000 | $52.74 | $527,400.00 | | |
| 8/15/2014 | Thomas E Werner | CFO | Sell | 10,000 | $55.13 | $551,300.00 | | |
| 7/15/2014 | Thomas E Werner | CFO | Sell | 10,000 | $51.50 | $515,000.00 | | |
| 6/16/2014 | Thomas E Werner | CFO | Sell | 10,000 | $50.82 | $508,200.00 | | |
| 5/21/2014 | Thomas Werner | CFO | Sell | 30,000 | $47.98 | $1,439,400.00 | 54,614 | |
| 5/16/2014 | Connie Curran | Director | Sell | 2,000 | $47.44 | $94,880.00 | 46,390 | |
| 5/14/2014 | Barbara Bowles | Director | Sell | 2,000 | $47.77 | $95,540.00 | 26,219 | |
| 5/13/2014 | Richard Hoffman | CAO | Sell | 15,000 | $48.07 | $721,050.00 | 29,440 | |
| 5/12/2014 | Brian Smith | SVP | Sell | 40,000 | $48.00 | $1,920,000.00 | 52,635 | |
| 3/14/2014 | Matthew Stober | SVP | Sell | 19,217 | $42.28 | $812,494.76 | 57,363 | |
| 2/26/2014 | Thomas Werner | CFO | Sell | 20,000 | $42.53 | $850,600.00 | 42,785 | |
| 9/11/2013 | Richard J Hoffman | CAO | Sell | 9,850 | $39.38 | $387,893.00 | | |
| 8/16/2013 | Matthew Stober | SVP | Sell | 4,990 | $40.12 | $200,198.80 | 48,619 | |
| 6/7/2013 | Sumant Ramachandra | SVP | Sell | 23,702 | $35.69 | $845,924.38 | | |
(Data available from 1/1/2013 forward)
Hospira (NYSE HSP) News Headlines
| Source: |
|
Hospira (NYSE:HSP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Hospira (NYSE:HSP) Income Statement, Balance Sheet and Cash Flow Statement
Hospira (NYSE HSP) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
